Benefits and risks of oral contraceptives

被引:51
作者
Sherif, K [1 ]
机构
[1] Med Coll Penn & Hahnemann Univ, Inst Womens Hlth, Philadelphia, PA 19129 USA
关键词
cardiovascular disease; low-dose ethinyl estradiol; cigarette smoking; oral contraceptives; third-generation progestogens;
D O I
10.1016/S0002-9378(99)70694-0
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The major benefits of modern low-dose oral contraceptives include relative safety and a high degree of efficacy, decreasing the need for abortion or surgical sterilization; reduced risks of bacterial (but not viral) pelvic inflammatory disease and of endometrial and ovarian cancer; improved menstrual regularity with less dysmenorrhea and blood flow; and, when low-dose combination (not progestogen-only) oral contraceptives are used, reduced acne and hirsutism. Major risks are cardiovascular. Preliminary data from nonrandomized studies suggest that oral contraceptives containing third-generation progestogens are associated with increased risk of venous thromboembolism, particularly in carriers of the coagulation factor V Leiden mutation. The risk of arterial thrombosis, such as myocardial infarction or stroke, may be directly related to estrogen dose, particularly in women who have hypertension, smoke, or are >35 years old. Considering that only users aged greater than or equal to 30 years who smoke greater than or equal to 25 cigarettes/d have a higher estimated mortality rate than that of pregnant women, the benefits of oral contraceptives appear to outweigh their risks.
引用
收藏
页码:S343 / S348
页数:6
相关论文
共 22 条
  • [1] Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus
    Andersson, B
    Mattsson, LA
    Hahn, L
    Marin, P
    Lapidus, L
    Holm, G
    Bengtsson, BA
    Bjorntorp, P
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (02) : 638 - 643
  • [2] ENHANCEMENT BY FACTOR-V LEIDEN MUTATION OF RISK OF DEEP-VEIN THROMBOSIS ASSOCIATED WITH ORAL-CONTRACEPTIVES CONTAINING 3RD-GENERATION PROGESTAGEN
    BLOEMENKAMP, KWM
    ROSENDAAL, FR
    HELMERHORST, FM
    BULLER, HR
    VANDENBROUCKE, JP
    [J]. LANCET, 1995, 346 (8990): : 1593 - 1596
  • [3] Oral contraceptives and rheumatoid arthritis: Results from a primary care-based incident case-control study
    Brennan, P
    Bankhead, C
    Silman, A
    Symmons, D
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 1997, 26 (06) : 817 - 823
  • [4] *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P791
  • [5] Chae CU, 1997, THROMB HAEMOSTASIS, V78, P770
  • [6] FARLEY TMM, 1995, LANCET, V346, P1582
  • [7] Hatcher R.A., 1994, CONTRACEPTION TECHNO
  • [8] Serum leptin levels in women with polycystic ovary syndrome: The role of insulin resistance hyperinsulinemia
    Laughlin, GA
    Morales, AJ
    Yen, SSC
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (06) : 1692 - 1696
  • [9] ORAL CONTRACEPTION AND RISK OF A CEREBRAL THROMBOEMBOLIC ATTACK - RESULTS OF A CASE-CONTROL STUDY
    LIDEGAARD, O
    [J]. BRITISH MEDICAL JOURNAL, 1993, 306 (6883) : 956 - 963
  • [10] Mishell D R Jr, 1992, Int J Fertil, V37 Suppl 1, P7